JP2024517871A5 - - Google Patents
Info
- Publication number
- JP2024517871A5 JP2024517871A5 JP2023568310A JP2023568310A JP2024517871A5 JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5 JP 2023568310 A JP2023568310 A JP 2023568310A JP 2023568310 A JP2023568310 A JP 2023568310A JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185941P | 2021-05-07 | 2021-05-07 | |
| US63/185,941 | 2021-05-07 | ||
| US202263313087P | 2022-02-23 | 2022-02-23 | |
| US63/313,087 | 2022-02-23 | ||
| PCT/US2022/072121 WO2022236292A2 (en) | 2021-05-07 | 2022-05-05 | Compositions and methods comprising protease-activated therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517871A JP2024517871A (ja) | 2024-04-23 |
| JPWO2022236292A5 JPWO2022236292A5 (https=) | 2025-05-15 |
| JP2024517871A5 true JP2024517871A5 (https=) | 2025-05-15 |
Family
ID=83932456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568310A Pending JP2024517871A (ja) | 2021-05-07 | 2022-05-05 | プロテアーゼ活性化治療剤を含む組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240228586A1 (https=) |
| EP (1) | EP4333873A4 (https=) |
| JP (1) | JP2024517871A (https=) |
| WO (1) | WO2022236292A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000991A (es) * | 2019-07-25 | 2022-05-24 | Univ Chicago | Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa. |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| CR20250279A (es) * | 2023-01-20 | 2025-08-25 | Boehringer Ingelheim Int | Proteínas de fusión fc de il-12 |
| WO2025242835A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011517934A (ja) * | 2008-03-03 | 2011-06-23 | カンザス ステイト ユニバーシティ リサーチ ファウンデーション | プロテアーゼアッセイ |
| TWI759810B (zh) * | 2014-08-08 | 2022-04-01 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
| CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2022000991A (es) * | 2019-07-25 | 2022-05-24 | Univ Chicago | Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa. |
| US20220356221A1 (en) * | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
-
2022
- 2022-05-05 US US18/559,180 patent/US20240228586A1/en active Pending
- 2022-05-05 EP EP22799803.6A patent/EP4333873A4/en active Pending
- 2022-05-05 WO PCT/US2022/072121 patent/WO2022236292A2/en not_active Ceased
- 2022-05-05 JP JP2023568310A patent/JP2024517871A/ja active Pending